Close

Citius Pharmaceuticals (CTXR) Reports Phase 3 Update On Mino-Lok Clinical Trial Following FDA Meeting

September 5, 2017 7:01 AM EDT Send to a Friend
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced today it has received feedback from the U. S. Food and Drug Administration ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login